Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Quantum BioPharma as a Graham-style analyst, and the first thing I notice is the absence of a durable earnings record. At the close on 2026-10-13, the shares were $2.89, giving a market capitalization of $18.4M. The supplied per-share loss figure is -$4.49, so the FairStock P/E is negative at -0.64, which means earnings tell me nothing about value. The FairStock P/B is 2.75, so the market is paying almost three times book for a business producing deeply negative returns: ROE -621.46% and ROCE -51.84%. Free cash flow is -$5.5M on a trailing basis, and the FCF yield is -29.8% of market cap, so cash is going out the door, not coming in. The balance sheet is not heavily levered at D/E 0.16, and beta is 0.45, but the Piotroski F-Score of 1/9 and Altman Z-Score of -19.46 point to severe financial weakness. The FairStock Score is 63/100, yet the Lynch category is none because there are only 0 years of filed results and three are needed; that tells me there is not enough history to judge. Revenue growth is not available. The 52-week range of $2.07 to $15.50 shows how far the stock has fallen. This is a speculative biotech pipeline story around Lucid-MS, not a proven compounding business. Without positive cash flow, a moat, or a long filed record, the price does not look cheap; it looks like a call option on clinical and commercial success. I would need much more evidence before calling it a value investment.

In plain English: Quantum BioPharma is a small biotech company researching treatments for brain, inflammatory and metabolic disorders. The business looks weak right now because it loses money and burns cash, with very little filed history to judge. At $2.89 a share, the price does not look cheap against those weak numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer